This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Arvidsson, J. Articles by Flesch, G. Search for Related Content PubMed PubMed Citation Articles by Arvidsson, J. Articles by Flesch, G. Social Bookmarking                         What's this?

Replacing Carbamazepine Slow-Release Tablets With Carbamazepine Suppositories: A Pharmacokinetic and Clinical Study in Children With Epilepsy

Department of Paediatrics, County Hospital Ryhov, Jönköping

Heimo L. Nilsson, PhD

Ciba-Geigy AB, Pharmaceuticals Division, Västra Frölunda

Per Sandstedt, MD, PhD

Department of Paediatrics, University Hospital, Linköping

Gunilla Steinwall, MD

Department of Paediatrics, County Hospital Ryhov, Jönköping

Bernt Tonnby, MD

Department of Paediatrics, County Hospital, Halmstad, Sweden

Gerard Flesch, PhD

Ciba-Geigy Ltd, Pharma Division, Basel, Switzerland

A suppository for rectal administration of carbamazepine has been developed for situations in which it is unsuitable to use the oral route of administration. In an open, controlled, within-patient study, the pharmacokinetics, clinical efficacy, and tolerability of carbamazepine slow-release tablets were compared with those of carbamazepine suppositories in children with epilepsy. The pharmacokinetic part of the study comprised 22 children, and an additional nine children were included in the clinical part of the study. Treatment with slow-release tablets was replaced for 7 days with carbamazepine suppositories in bioequivalent dosage. Clinical factors such as the rate of seizures and the local tolerability were studied, and an overall assessment of efficacy was made. In the pharmacokinetic part, 24-hour plasma concentration curves for carbamazepine and carbamazepine-10,11-epoxide were recorded. The plasma concentration profiles (minimum, maximum, and mean concentrations, fluctuation index, and area under the curve) for carbamazepine and the other metabolites did not show any significant differences between oral and rectal administration when the suppository dose was increased by 25% compared to the tablets. No increase in seizure frequency was detected, and the overall assessment was very good to good in 25 of the 29 epileptic children. Increased flatulence during treatment with suppositories was noted in two children, one had anal irritation, and one had nausea/vomiting. Treatment with carbamazepine slow-release tablets in children with epilepsy can be replaced by carbamazepine suppositories in 25% higher dosage, with good clinical effect and appropriate pharmacokinetic values, when it is unsuitable to use the common oral route of administration. (J Child Neurol 1995; 10: 114-117).

Journal of Child Neurology, Vol. 10, No. 2, 114-117 (1995)
DOI: 10.1177/088307389501000209


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?